Top

Published in:

01-08-2013 | Sarcomas (SR Patel, Section Editor)

The Treatment Outcome for Adult Patients with Ewing’s Sarcoma

Authors: Kristen N. Ganjoo, Shreyaskumar Patel

Published in: Current Oncology Reports | Issue 4/2013

Abstract

Ewing’s sarcoma is the second most common bone malignancy in children, but is extremely rare in adults. The outcome of patients with localized disease has improved over the past decades due to better combination chemotherapies, and better methods of local control. Unfortunately, patients with metastatic disease have a very poor outcome with current antineoplastic therapies. In this article, we will review the primary treatment for adult patients with Ewing’s sarcoma, both for localized and metastatic disease. The prognostic factors in adult patients with EWS will also be reviewed.

Ewing J. Diffuse endothelioma of bone. Proc of NY Path Soc. 1921;12:17.

Codman EA. Bone sarcomas: An interpretation of the nomenclature used by the committee on the registry of bone sarcomas of the American College of Surgeons. New York: Paul B Hoeber, Inc.; 1925.

Askin FB, Rosai J, Sibley RK, Dehner LP, McAlister WH. Malignant small cell tumor of the thoracopulmonary region in childhood A distinctive clininopathologic entity of uncertain histogenesis. Cancer. 1979;43:2438–51.PubMedCrossRef

Turc-Carel C, Philip I, Berger MP, Philip T, Lenoir GM. Chromosome translocation in Ewing’s sarcoma. N Engl J Med. 1983;309:497–8.

Aurias A, Rimbaut C, Buffe D, Dubousset J, Mazabraud A. Chromosomal translocations Ewing’s sarcoma. N Engl J Med. 1983;309:496–7.

Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature. 1992;359(6391):162–5.PubMedCrossRef

Zucman J, Delattre O, Desmaze C, Plougastel B, Joubert I, Melot T, et al. Cloning and characterization of the Ewing's sarcoma and peripheral neuroepithelioma t(11;22) translocation breakpoints. Genes Chromosomes Cancer. 1992;5(4):271–7.PubMedCrossRef

Hromas R, Klemsz M. The ETS oncogene family in development, proliferation and neoplasia. Int J Hematol. 1994;59(4):257–65.PubMed

Jawad MU, Cheung MC, Min ES, Schneiderbauer MM, Koniaris LG, Scully SP. Ewing’s sarcoma demonstrates racial disparities in incidence-related and sex-related differences in outcome. An analysis of 1631 cases from the SEER database, 1973–2005. Cancer. 2009;115:3526–36.PubMedCrossRef

10.

Cotterill SJ, Ahrens S, Paulussen M, Jurgens HF, Voute PA, Gadner H, et al. Prognostic factors in Ewing’s tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing’s Sarcoma Study Group. J Clin Oncol. 2000;18:3108–14.PubMed

11.

American Cancer Society. Facts & Figures 2013. http://www.cancer.org/research/cancerfactsfigures/indexer

12.

Bacci G, Ferrari S, Bertani F, Rimondini S, Longhi A, Bacchini P, et al. Prognostic factors in nonmetastatic Ewing’s sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Insttuto Ortopedicp Rizzoli. J Clin Oncol. 2000;18:4–11.PubMed

13.

Bacci G, Longhi A, Ferrari S, Mercuri M, Versari M, Bertoni F. Prognostic factors in non-metastatic Ewing’s sarcoma tumor of bone: an analysis of 579 patients treated at a single institution with adjuvant or neoadjuvant chemotherapy between 1972 and 1998. Acta Oncol. 2006;45:469–75.PubMedCrossRef

14.

Obata H, Ueda T, Kawai A, Ishii T, Ozaki T, Abe S, et al. Clinical outcome of patients with Ewing’s sarcoma family of tumors of bone in Japan: the Japanese Musculoskeletal Oncology Group Cooperative Study. Cancer. 2007;109(4):767–75.PubMedCrossRef

15.

Rosito P, Mancini AF, Rondelli R, Abate ME, Pession A, Bedei L, et al. Italian cooperative study for the treatment of children and young adults with localized Ewing’s sarcoma of bone: a preliminary report of 6 years of experience. Cancer. 1999;86(3):421–8.PubMedCrossRef

16.

Marina N, Grier H, Womer R, Granowetter L, Krailo M. Prognostic factors in Ewing’s sarcoma family of tumors (ES) treated in consecutive children’s oncology group (COG) studies: A report of 1444 patients. CTOS. 2010;40:886392.

17.

Fizazi K, Dohollou N, Blay JY, Guerin S, Le Cesne A, Andre F, et al. anf Nguyes BB. Ewing’s family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients. J Clin Oncol. 1998;16:3736–43.PubMed

18.

Landentein R, Potschger U, Le Deley MC, Whelan J, Paulussen M, Oberlin O, et al. primary disseminated multifocal Ewing’s sarcoma: results of Euro-Ewing 99 trial. J Clin Oncol. 2010;28:3284–91.CrossRef

19.

Baldini EH, Demetri GD, Fletcher CDM, Foran J, Marcus KC, Singer S. Adults with Ewing’s sarcoma/Primitive neuroectodermal tumor. Adverse effect of older age and primary extraosseous disease on outcome. Ann Surg. 1999;230(1):79–86.PubMedCrossRef

20.

Martin RCG, Brennan MF. Adult soft tissue Ewing’s sarcoma or Primitive Neuroectodermal tumors. Arch Surg. 2003;138:281–5.PubMedCrossRef

21.

Verrill MW, Judson IR, Harmer CL, Fisher C, Thomas JM, Wiltshaw E. Ewing’s sarcoma and Primitive neuroectodermal tumor in adults: are they different from Ewing’s sarcoma and Primitive neuroectodermal tumor in children. J Clin Oncol. 1997;15:2611–21.PubMed

22.

Siegel RD, Ryan LM, Antman KH. Adults with Ewing’s sarcoma. An analysis of 16 patients at the Dana Farber Cancer Institute. Am J Clin Oncol. 1988;11(6):614–7.PubMedCrossRef

23.

Gupta AA, Pappo A, Saunders N, Hopyan S, Ferguson P, Wunder J, et al. Clinical outcome of children and adults with localized Ewing’s sarcoma. Cancer. 2010;116:3189–94.PubMedCrossRef

24.

Argon A, Basaran M, Yaman F, Dizdar Y, Sakar B, Camlica H, et al. Ewing’s sarcoma of the axial system in patients older than 15 years: dismal prognosis despite intensive multiagent chemotherapy and aggressive local treatment. Jpn J Clin Oncol. 2004;34(11):667–72.PubMedCrossRef

25.

Hense HW, Ahrens S, Paulussen M, Lehnert M, Jurgens H. Factors associated with tumor volume and primary metastases in Ewing’s tumors: Results from the (EI)CESS studies. Ann of Oncol. 1999;10:1073–7.CrossRef

26.

Verril MW, Judson IR, Harmer CL, Fisher C, Thomas JM, Wiltshaw E. Ewing’s sarcoma and primitive neuroectodermal tumor in adults: arethey different from Ewing’s sarcoma and Primitive neuroectodermal tumor in children? J Clin Oncol. 1997;15:2611–21.

27.

Bacci G, Ferrari S, Longhi A, Versari M, Forni C, Donati D, et al. Local and systemic control in Ewing’s sarcoma of the femur treated with chemotherapy, and locally by radiotherapy and/ or surgery. J Bone Joint Surg Br. 2003;85-B:107–14.CrossRef

28.

Scully SP, Temple HT, O’Keefe RJ, Scarborough MT, Mankin HJ, Gebhardt MC. Role of surgical resection in pelvic Ewing’s sarcoma. J Clin Oncol. 1995;13:2336–41.PubMed

29.

Yock TI, Krailo M, Fryer CJ, Donaldson SS, Miser JS, Chen Z, et al. Local control in pelvic Ewing’s sarcoma: analysis from INT-0091- A report from the children’s oncology group. J Clin Oncol. 2006;24:3838–43.PubMedCrossRef

30.

•• Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJH, Pritchard DJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and Primitive neuroectodermal tumor of the bone. N Engl J Med. 2003;348(8):694–701. This randomized study with ifosfamide and etoposide added to standard therapy, shows an improvement in outcome in adult patients with localized disease. In addition, this study demonstrates that most adults can tolerate intensive chemotherapy regimens. PubMedCrossRef

31.

Juergens G, Weston C, Lewis I, Whelan J, Paulussen M, Oberlin O, et al. Safety Assessment of Intensive Induction With Vincristine, Ifosfamide, Doxorubicin, and Etoposide (VIDE) in the Treatment of Ewing Tumors in the EURO-E.W.I.N.G. 99 Clinical Trial. Pediatr Blood Cancer. 2006;47:22–9.PubMedCrossRef

32.

• Granowetter L, Womer R, Devidas M, Krailo M, Wang C, Bernstein M, et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing’s sarcoma family of tumors: a children’s oncology group study. J Clin Oncol. 2009;27:2536–41. This randomized study demonstrates that dose intensity, as given in this study, does not improve outcome in adult patients with Ewing’s sarcoma. PubMedCrossRef

33.

Sinkovics JG, Plager C, Ayala AG, Lindberg RD, Samuels ML. Ewing’s sarcoma: its course and treatment in 50 adult patients. Oncology. 1980;37:114–9.PubMedCrossRef

34.

Bacci G, Belladelli A, Forni C, Ferrari S, Longhi A, Bacchini P, et al. Adjuvant and neoadjuvant chemotherapy for Ewing’s sarcoma family tumors in patients aged between 40 and 60. Cancer. 2007;109:780–6.PubMedCrossRef

Title: The Treatment Outcome for Adult Patients with Ewing’s Sarcoma
Authors: Kristen N. Ganjoo
Shreyaskumar Patel
Publication date: 01-08-2013
Publisher: Springer US
Published in: Current Oncology Reports / Issue 4/2013
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-013-0317-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2013

The Adolescent and Young Adult With Cancer: State of the Art - Psychosocial Aspects

EGFR Tyrosine Kinase Inhibitors: Difference in Efficacy and Resistance

Cancer in Adolescents and Young Adults in Countries with Limited Resources

The Role of Radiation Therapy in Small Cell Lung Cancer

The Adolescent and Young Adult with Cancer: State of the Art - Bone Tumors

The Role of Consolidation Treatment in Locally Advanced Unresectable NSCLC

Keynote webinar | Spotlight on antibody–drug conjugates in cancer